Novo Nordisk's (NVO) controlling shareholder, Novo Holdings, is looking to double the size of Catalent over five years as President-elect Donald Trump is likely to focus on US manufacturing, Reuters reported, citing an interview with a Novo Holdings senior partner.
Jonathan Levy said the company did not want to set a revenue target before agreeing on a corporate strategy with Catalent's management but noted that "doubling the size of your business over five years is always a nice barometer to work on," according to the report.
Levy said Catalent is set to hold its next board meeting in February, Reuters added.
Novo Holdings and Catalent did not immediately respond to MT Newswires' requests for comments.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。